ArticleCancers2024

Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma.

Yuki Shirane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.